PDCD1 and hepatocellular carcinoma: Furthermore, given that pembrolizumab represents diverse anticancer activities for a subset of uHCC [21], the need to stratify patients based on PD-1 expression status and the actual antitumour efficacy of pembrolizumab plus lenvatinib plus HAIC, even in a biomarker-selected HCC setting, has not been evaluated.